"Starting Monday, the lowest dose vial will cost $299 a month for those who pay cash, Lilly said in a statement, a discount of about $50. The next higher dose will cost $399 a month, roughly 20% less than the previous self-pay price. Lilly isn't changing the price of higher doses, which are sold for $499 a month. It's the latest move in a price war with Denmark's Novo Nordisk, which is making it significantly less expensive for people to start the blockbuster medicines."
"Ilya Yuffa, president of Lilly USA, said the discounts underscore the company's commitment to improving access to obesity care. It's the second time this year that the company has cut prices for Zepbound vials on LillyDirect. "We will keep working to provide more options - expanding choices for delivery devices and creating new pathways for access - so more people can get the medicines they need," he said in a statement."
Eli Lilly reduced cash-pay prices for lower-dose Zepbound vials, setting the lowest dose at $299 monthly and the next dose at $399 while keeping higher doses at $499. The discounts are offered through LillyDirect and target patients who typically begin treatment at lower doses before moving to stronger formulations. The cuts follow price moves by Novo Nordisk, which sells introductory Ozempic and Wegovy at $199 for the first two months via NovoCare and then $349 monthly. Lilly framed the reductions as steps to improve access to obesity care and plans to expand delivery device choices and access pathways. The moves occur amid intense competition and expectations that the global obesity market will reach roughly $100 billion.
Read at Los Angeles Times
Unable to calculate read time
Collection
[
|
...
]